EHS
EHS

Sacituzumab govitecan appears safe, effective in heavily pretreated breast cancer subtype

Aditya Bardia Treatment with sacituzumab govitecan, a novel antibody-drug conjugate, resulted in objective responses among women with heavily pretreated hormone receptor-positive, HER-2-negative breast cancer, according to findings presented at the ASCO Annual Meeting.
The adverse events observed with sacituzumab govitecan (IMMU-132, Immunomedics) were tolerable and similar to those observed in earlier reports.
“Sacituzumab govitecan is a novel antibody-drug conjugate consisting of SN-38, the active metabolite of irinotecan, conjugated to a humanized monoclonal antibody targeting
EHS
Back to top button